Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors

NCT00415571 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypogonadism
Erectile Dysfunction

Interventions

DRUG: Fispemifene (once daily for 8 weeks)

Sponsor

QuatRx Pharmaceuticals Company

Collaborators

[object Object]